Showing 1911-1920 of 5846 results for "".
- From ASLMS 2025: Dr. Joel Cohen Highlights New Fractional Laser Techniques, Including Laser-enabled Tissue Coringhttps://practicaldermatology.com/news/from-aslms-dr-joel-cohen-highlights-new-fractional-laser-techniques-for-scars-at-aslms/2474327/During a fractional laser section of the recent program of the 2025 American Society for Laser Medicine and Surgery (ASLMS) Annual Meeting in Orlando, board-certified dermatologist, Mohs surgeon, and laser expert Joel L. Cohen, MD, FAAD, FACMS, presented clinical insights into fractional laser us
- From ASLMS 2025: E. Victor Ross, MD, Talks Landscape of Fractional Laser Treatmentshttps://practicaldermatology.com/news/from-aslms-e-victor-ross-md-explores-landscape-of-fractional-laser-treatments/2474326/At the 2025 American Society for Laser Medicine and Surgery (ASLMS) Annual Meeting in Orlando, E. Victor Ross, MD, shared insights on the evolving role of fractional lasers in dermatologic practice, highlighting both their advantages and limitations. Risk, Recovery, and Pigmentatio
- AVAVA Receives FDA Clearance for Acne Scar Treatment on All Skin Types Using Focal Point Technologyhttps://practicaldermatology.com/news/avava-receives-fda-clearance-for-acne-scar-treatment-on-all-skin-types-using-focal-point-technology/2474319/The U.S. Food and Drug Administration (FDA) has cleared AVAVA’s Focal Point Technology™ for the treatment of acne scars, marking a significant milestone in energy-based skin therapy. The technology, developed by Boston-based AVAVA, is now indicated for acne scarring in all Fitzpatrick sk
- Report: 5-FU and Imiquimod Combo May Offer Enhanced Actinic Keratosis Clearancehttps://practicaldermatology.com/news/report-5-fu-and-imiquimod-combo-may-offer-enhanced-actinic-keratosis-clearance/2474234/Combining 5-fluorouracil (5-FU) and imiquimod may enhance therapeutic efficacy for actinic keratoses (AK), according to emerging data. "To date, the combination of 5-FU and imiquimod, 2 of the most used monotherapies, remain
- Machine Learning Model Flags HS Up to Two Years Before Diagnosis: Reporthttps://practicaldermatology.com/news/machine-learning-model-flags-hidradenitis-suppurativa-up-to-two-years-before-diagnosis/2474208/A machine learning model analyzing U.S. insurance claims data was able to predict hidradenitis suppurativa (HS) up to two years before formal diagnosis, a new study shows. "Because the individual symptoms of cysts and abscesse
- FDA Approves Dupilumab for CSU in Adults 12 and Olderhttps://practicaldermatology.com/news/FDA-Approves-Dupilumab-CSU-Adults-12-Older/2474212/The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent, Regeneron Pharmaceuticals, Inc. and Sanofi) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) whose disease is not adequately controlled with histamine-1 (H1) ant
- Study: AD Patients Switching From Dupilumab to Upadacitinib Have Improved EASI, Itch Scoreshttps://practicaldermatology.com/news/Study-AD-Patients-Switching-From-Dupilumab-Upadacitinib-Have-Improved-EASI-Itch-Scores/2474207/Treatment of moderate-to-severe atopic dermatitis (AD) with upadacitinib in patients who received dupilumab for 16 weeks without an adequate response demonstrated improved efficacy in skin and itch endpoints, according to new research. “Switching from Dupilumab to Upadacitinib in Adults an
- Biologic Costs for Plaque Psoriasis Doubled Since 2007, Study Findshttps://practicaldermatology.com/news/biologic-costs-for-plaque-psoriasis-double-since-2007-study-finds/2474189/A new analysis shows the average net annual cost of first-line biologic treatments for plaque psoriasis more than doubled between 2007 and 2021, rising from $21,236 to $47,125. The study researchers, publishing online in J
- Analysis: Proximity to Tanning Facilities Correlates with Increased Melanoma Incidence in New Englandhttps://practicaldermatology.com/news/analysis-proximity-to-tanning-facilities-correlates-with-increased-melanoma-incidence-in-new-england/2473824/Results from a new analysis suggest a correlation between proximity to tanning facilities and higher melanoma inc
- Further Positive Delgocitinib Data Presented at AADhttps://practicaldermatology.com/news/Further-Positive-Delgocitinib-Data-Presented-AAD/2471609/Late-breaking data presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, showcased responses in a subgroup of patients from the DELTA 1 and Delta 2 trials on lebrikizumab for chronic hand eczema. Alongside this presentation, new systemic exposure